--- title: "PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest" type: "News" locale: "en" url: "https://longbridge.com/en/news/297431820.md" description: "PolyPid Ltd. (NASDAQ:PYPD) experienced a significant 44.0% drop in short interest during August, falling to 231,379 shares as of August 14th. The days-to-cover ratio stands at 1.4 days, with approximately 1.6% of stock sold short. Additionally, several institutional investors initiated new positions in the second quarter. PolyPid recently reported quarterly earnings of ($0.35) per share, beating estimates, while analysts maintain an average 'Moderate Buy' rating with a target price of $11.33." datetime: "2026-08-30T16:20:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297431820.md) - [en](https://longbridge.com/en/news/297431820.md) - [zh-HK](https://longbridge.com/zh-HK/news/297431820.md) generator: "portal-rs" --- # PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) was the target of a large decline in short interest in August. As of August 14th, there was short interest totaling 231,379 shares, a decline of 44.0% from the July 30th total of 412,853 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average trading volume of 170,743 shares, the days-to-cover ratio is presently 1.4 days. ## Institutional Inflows and Outflows A number of large investors have recently made changes to their positions in the stock. AIGH Capital Management LLC acquired a new position in PolyPid in the second quarter valued at about $7,644,000. J. Goldman & Co LP acquired a new position in shares of PolyPid during the 2nd quarter worth about $504,000. ADAR1 Capital Management LLC acquired a new position in shares of PolyPid during the 2nd quarter worth about $528,000. Symmetry Peak Management LLC bought a new stake in shares of PolyPid in the 2nd quarter valued at about $512,000. Finally, AXQ Capital LP bought a new stake in shares of PolyPid in the 2nd quarter valued at about $87,000. Institutional investors and hedge funds own 26.47% of the company's stock. ## PolyPid Price Performance Shares of NASDAQ PYPD traded down $0.05 during mid-day trading on Friday, hitting $5.07. The company's stock had a trading volume of 63,535 shares, compared to its average volume of 151,331. PolyPid has a one year low of $3.06 and a one year high of $5.73. The company's fifty day simple moving average is $4.82 and its 200-day simple moving average is $4.60. The stock has a market cap of $96.75 million, a price-to-earnings ratio of -3.43 and a beta of 1.41. PolyPid (NASDAQ:PYPD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. On average, sell-side analysts predict that PolyPid will post -0.92 EPS for the current year. ## Analysts Set New Price Targets A number of equities research analysts recently weighed in on PYPD shares. Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. Weiss Ratings raised PolyPid from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, June 23rd. Finally, HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of PolyPid in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $11.33. **Get Our Latest Stock Analysis on PYPD** ## PolyPid Company Profile (Get Free Report) PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients. Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia. ## See Also - Five stocks we like better than PolyPid - Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally - Rubrik’s AI Security Bet Could Power the Next Leg Higher - Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All - Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in PolyPid Right Now? Before you consider PolyPid, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PolyPid wasn't on the list. While PolyPid currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PYPD.US](https://longbridge.com/en/quote/PYPD.US.md) - [RBRK.US](https://longbridge.com/en/quote/RBRK.US.md) - [AAPL.US](https://longbridge.com/en/quote/AAPL.US.md) - [SNOW.US](https://longbridge.com/en/quote/SNOW.US.md) ## Related News & Research - [PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential](https://longbridge.com/en/news/293345524.md) - [PolyPid (PYPD) Q2 2026 Earnings Call: D-PLEX100 Priority Review and Azurity Deal](https://longbridge.com/en/news/295904620.md) - [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md) - [BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era](https://longbridge.com/en/news/297178071.md) - [Propanc Biopharma Announces Positive Preclinical Data For PRP In Pancreatic Cancer, Stock Soars](https://longbridge.com/en/news/297195775.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**